Safety and Efficacy of Levosimendan in Patients With Acute Myocardial Infarction Complicated by Symptomatic Left Ventricular Failure.

Trial Profile

Safety and Efficacy of Levosimendan in Patients With Acute Myocardial Infarction Complicated by Symptomatic Left Ventricular Failure.

Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Sep 2014

At a glance

  • Drugs Levosimendan (Primary)
  • Indications Decompensated heart failure; Myocardial infarction
  • Focus Biomarker; Pharmacodynamics
  • Acronyms LEAF
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 29 Aug 2012 Primary endpoint 'Wall-motion-score' has been met according to results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
    • 29 Aug 2012 Results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top